European Medicines Agency to Review Nuvation Bio and Eisai's Lung Cancer Treatment

Nuvation Bio and Eisai's marketing authorization application for taletrectinib, a treatment for non-small cell lung cancer, has been accepted for review in Europe. The European Medicines Agency validated the application, which was submitted by the companies. Taletrectinib is an oral tyrosine kinase inhibitor that targets ROS1-positive non-small cell lung cancer.